Precision Medicine in Erythropoietin Deficiency and Treatment Resistance : A Novel Approach to Management of Anaemia in Chronic Kidney Disease
The study of anaemia is a well-developed discipline where the concepts of precision medicine have, in part, been researched extensively. This review discusses the treatment of erythropoietin (EPO) deficiency anaemia and resistance in cases of chronic kidney disease (CKD). Traditionally, erythropoietin-stimulating agents (ESAs) and iron supplementation have been used to manage anaemia in cases of CKD. However, these treatments pose potential risks, including cardiovascular and thromboembolic events. Newer treatments have emerged to address these risks, such as slow-release and low-dosage intravenous iron, oral iron supplementation, and erythropoietin-iron combination therapy. Another novel approach is the use of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). This review highlights the need for precision medicine targeting the genetic components of EPO deficiency anaemia in CKD and discusses individual variability in genes such as the erythropoietin gene (EPO), the interleukin-β gene (IL-β), and the hypoxia-inducible factor gene (HIF). Pharmacogenetic testing aims to provide targeted therapies and interventions that are tailored to the specific characteristics of an individual, thus optimising treatment outcomes and minimising resistance and adverse effects. This article concludes by suggesting that receptor modification has the potential to revolutionise the treatment outcomes of patients with erythropoietin deficiency anaemia through the integration of the mentioned approach.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Current issues in molecular biology - 45(2023), 8 vom: 07. Aug., Seite 6550-6563 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yugavathy, Nava [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Erythropoietin deficiency anaemia |
|---|
| Anmerkungen: |
Date Revised 28.08.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cimb45080413 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361214812 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361214812 | ||
| 003 | DE-627 | ||
| 005 | 20231226084646.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cimb45080413 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1203.xml |
| 035 | |a (DE-627)NLM361214812 | ||
| 035 | |a (NLM)37623232 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yugavathy, Nava |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Precision Medicine in Erythropoietin Deficiency and Treatment Resistance |b A Novel Approach to Management of Anaemia in Chronic Kidney Disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.08.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The study of anaemia is a well-developed discipline where the concepts of precision medicine have, in part, been researched extensively. This review discusses the treatment of erythropoietin (EPO) deficiency anaemia and resistance in cases of chronic kidney disease (CKD). Traditionally, erythropoietin-stimulating agents (ESAs) and iron supplementation have been used to manage anaemia in cases of CKD. However, these treatments pose potential risks, including cardiovascular and thromboembolic events. Newer treatments have emerged to address these risks, such as slow-release and low-dosage intravenous iron, oral iron supplementation, and erythropoietin-iron combination therapy. Another novel approach is the use of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). This review highlights the need for precision medicine targeting the genetic components of EPO deficiency anaemia in CKD and discusses individual variability in genes such as the erythropoietin gene (EPO), the interleukin-β gene (IL-β), and the hypoxia-inducible factor gene (HIF). Pharmacogenetic testing aims to provide targeted therapies and interventions that are tailored to the specific characteristics of an individual, thus optimising treatment outcomes and minimising resistance and adverse effects. This article concludes by suggesting that receptor modification has the potential to revolutionise the treatment outcomes of patients with erythropoietin deficiency anaemia through the integration of the mentioned approach | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a HIF-PHI | |
| 650 | 4 | |a erythropoietin deficiency anaemia | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a pharmacogenetics | |
| 650 | 4 | |a precision medicine | |
| 700 | 1 | |a Abdullah, Bashar Mudhaffar |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Soo Kun |e verfasserin |4 aut | |
| 700 | 1 | |a Abdul Gafor, Abdul Halim Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Muh Geot |e verfasserin |4 aut | |
| 700 | 1 | |a Bavanandan, Sunita |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Hin Seng |e verfasserin |4 aut | |
| 700 | 1 | |a Huri, Hasniza Zaman |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current issues in molecular biology |d 1999 |g 45(2023), 8 vom: 07. Aug., Seite 6550-6563 |w (DE-627)NLM113667744 |x 1467-3045 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2023 |g number:8 |g day:07 |g month:08 |g pages:6550-6563 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cimb45080413 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2023 |e 8 |b 07 |c 08 |h 6550-6563 | ||